ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Given Average Rating of “Buy” by Analysts

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) has received a consensus rating of “Buy” from the nine ratings firms that are currently covering the company, MarketBeat.com reports. One analyst has rated the stock with a hold recommendation, seven have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $80.13.

Several brokerages recently commented on ANIP. HC Wainwright reiterated a “buy” rating and set a $94.00 target price on shares of ANI Pharmaceuticals in a report on Monday, March 17th. JPMorgan Chase & Co. initiated coverage on shares of ANI Pharmaceuticals in a research note on Wednesday, March 12th. They set an “overweight” rating and a $85.00 price objective on the stock. Guggenheim reissued a “buy” rating and set a $86.00 target price on shares of ANI Pharmaceuticals in a research report on Monday, May 12th. Truist Financial upped their target price on shares of ANI Pharmaceuticals from $62.00 to $65.00 and gave the company a “hold” rating in a research note on Monday, April 21st. Finally, Wall Street Zen cut shares of ANI Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, April 24th.

Insiders Place Their Bets

In other news, insider Christopher Mutz sold 4,000 shares of ANI Pharmaceuticals stock in a transaction that occurred on Wednesday, May 14th. The shares were sold at an average price of $60.45, for a total value of $241,800.00. Following the transaction, the insider now owns 107,317 shares of the company’s stock, valued at $6,487,312.65. The trade was a 3.59% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, SVP Ori Gutwerg sold 881 shares of the firm’s stock in a transaction that occurred on Thursday, May 15th. The stock was sold at an average price of $60.07, for a total transaction of $52,921.67. Following the sale, the senior vice president now owns 89,897 shares of the company’s stock, valued at $5,400,112.79. The trade was a 0.97% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 5,681 shares of company stock worth $346,854. 11.10% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On ANI Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Hohimer Wealth Management LLC boosted its position in shares of ANI Pharmaceuticals by 5.2% in the 1st quarter. Hohimer Wealth Management LLC now owns 4,989 shares of the specialty pharmaceutical company’s stock valued at $334,000 after purchasing an additional 247 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of ANI Pharmaceuticals by 3.6% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 10,523 shares of the specialty pharmaceutical company’s stock valued at $582,000 after acquiring an additional 364 shares during the period. Natixis Advisors LLC lifted its position in shares of ANI Pharmaceuticals by 2.3% in the 4th quarter. Natixis Advisors LLC now owns 18,601 shares of the specialty pharmaceutical company’s stock valued at $1,028,000 after acquiring an additional 417 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in ANI Pharmaceuticals by 0.9% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 48,322 shares of the specialty pharmaceutical company’s stock worth $3,235,000 after purchasing an additional 423 shares during the period. Finally, Advisors Asset Management Inc. purchased a new position in ANI Pharmaceuticals during the 1st quarter worth approximately $28,000. 76.05% of the stock is owned by institutional investors and hedge funds.

ANI Pharmaceuticals Price Performance

ANIP opened at $64.66 on Friday. ANI Pharmaceuticals has a 52-week low of $52.50 and a 52-week high of $77.00. The company has a 50 day moving average of $64.67 and a two-hundred day moving average of $61.24. The company has a market cap of $1.40 billion, a P/E ratio of -50.91 and a beta of 0.55. The company has a quick ratio of 1.98, a current ratio of 2.66 and a debt-to-equity ratio of 1.46.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its quarterly earnings results on Friday, May 9th. The specialty pharmaceutical company reported $1.70 earnings per share for the quarter, topping analysts’ consensus estimates of $1.37 by $0.33. ANI Pharmaceuticals had a negative net margin of 3.12% and a positive return on equity of 21.35%. The firm had revenue of $197.12 million during the quarter, compared to analysts’ expectations of $179.75 million. During the same period in the prior year, the company earned $0.82 EPS. The firm’s revenue was up 43.4% on a year-over-year basis. On average, analysts expect that ANI Pharmaceuticals will post 3.86 earnings per share for the current year.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.